Keywords
published a meta-analysis reviewing the outcomes of early versus late initiation of renal replacement therapy (RRT). They included patients with and without acute kidney injury (AKI) for whom RRT was started with purification goals. They showed that early start of RRT was not associated with better morbidity or mortality outcomes.
Nevertheless, since the last decade and mainly in the last couple of years, the month when a study or a meta-analysis does not come out contemplating about the best RRT starting timing is rare, with early and late start showing better outcomes in alternating publications.
The eternal question remains. Early and late are still nonconsensual terms and seem to have different meanings according to the population studied (cardiac surgery patients, maybe because they have a higher rate of progressing AKI, seem to benefit from an earlier start of RRT than a mixed critical care population). 2, 3 What is consensual, is that we don't want to restrain dialysis until it is too late for someone who will eventually really need it. Similarly, we don't want to start dialysis to someone who would never need it and add a burden of potential catheter and technique complications, besides the financial and logistical costs.
We urgently need a recovery biomarker or panel of biomarkers that can approach us to personalized medicine and help us predict for individual patients the probability of short-term recovery. Namely, we need biomarkers that can help us predict the progression of AKI to persistent AKI and from here to acute kidney disease and chronic kidney disease. In a future that we forecast not long, clinical studies should include biomarkers in the definition of early and late start of RRT.
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